Safety Study to Compare the Gastrointestinal Tolerability of Oral Tegomil Fumarate and Dimethyl Fumarate (Tecfidera®) in Healthy Volunteers.

2023-508439-30-00 Protocol NXPTEGO/23/P1-4 Human pharmacology (Phase I) - Other Ended

Start 21 Aug 2024 · End 23 Dec 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol NXPTEGO/23/P1-4

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 210
Countries 1
Sites 1

Multiple Sclerosis

Key facts

Sponsor
Neuraxpharm Pharmaceuticals S.L.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
21 Aug 2024 → 23 Dec 2024
Decision date (initial)
2024-03-15
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Multiple Sclerosis

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Neuraxpharm Pharmaceuticals S.L.

Sponsor organisation
Neuraxpharm Pharmaceuticals S.L.
Address
Avinguda De Barcelona 69, Poligono Industrialde La Fuensanta Poligono Industrialde La Fuensanta
City
Sant Joan Despi
Postcode
08970
Country
Spain

Scientific contact point

Organisation
Neuraxpharm Pharmaceuticals S.L.
Contact name
Emili González-Pérez

Public contact point

Organisation
Neuraxpharm Pharmaceuticals S.L.
Contact name
Emili González-Pérez

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Portugal Ended 210 1
Rest of world 0

Investigational sites

Portugal

1 site · Ended
Blueclinical Investigacao E Desenvolvimento Em Saude Lda.
Allergy and Clinical Inmunology, Hospital Da Prelada 0 Floor And 3 rd Floor, Rua Sarmento De Beires 153, Porto

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Portugal 2024-08-21 2024-12-23 2024-08-22 2024-11-04

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-12-07 Portugal Acceptable with conditions
2024-03-15
2024-03-15
2 SUBSTANTIAL MODIFICATION SM-1 2024-06-05 Portugal Acceptable
2024-07-02
2024-07-02
3 NON SUBSTANTIAL MODIFICATION NSM-2 2024-12-04 Acceptable
2024-07-02
4 SUBSTANTIAL MODIFICATION SM-2 2025-02-13 Portugal Acceptable 2025-03-07